Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Morten Schmidt, Sigrun Alba Johannesdottir Schmidt, Kasper Adelborg, Jens Sundbøll, Kristina Laugesen, Vera Ehrenstein & Henrik Toft Sørensen. (2019) The Danish health care system and epidemiological research: from health care contacts to database records. Clinical Epidemiology 11, pages 563-591.
Read now
Read now
Articles from other publishers (28)
M. Lefort, S. Sharmin, J. B. Andersen, S. Vukusic, R. Casey, M. Debouverie, G. Edan, J. Ciron, A. Ruet, J. De Sèze, E. Maillart, H. Zephir, P. Labauge, G. Defer, C. Lebrun-Frenay, T. Moreau, E. Berger, P. Clavelou, J. Pelletier, B. Stankoff, O. Gout, E. Thouvenot, O. Heinzlef, A. Al-Khedr, B. Bourre, O. Casez, P. Cabre, A. Montcuquet, A. Wahab, J. P. Camdessanché, A. Maurousset, H. Ben Nasr, K. Hankiewicz, C. Pottier, N. Maubeuge, D. Dimitri-Boulos, C. Nifle, D. A. Laplaud, D. Horakova, E. K. Havrdova, R. Alroughani, G. Izquierdo, S. Eichau, S. Ozakbas, F. Patti, M. Onofrj, A. Lugaresi, M. Terzi, P. Grammond, F. Grand’Maison, B. Yamout, A. Prat, M. Girard, P. Duquette, C. Boz, M. Trojano, P. McCombe, M. Slee, J. Lechner-Scott, R. Turkoglu, P. Sola, D. Ferraro, F. Granella, V. Shaygannejad, J. Prevost, D. Maimone, O. Skibina, K. Buzzard, A. Van der Walt, R. Karabudak, B. Van Wijmeersch, T. Csepany, D. Spitaleri, S. Vucic, N. Koch-Henriksen, F. Sellebjerg, P. S. Soerensen, C. C. Hilt Christensen, P. V. Rasmussen, M. B. Jensen, J. L. Frederiksen, S. Bramow, H. K. Mathiesen, K. I. Schreiber, H. Butzkueven, M. Magyari, T. Kalincik & E. Leray. (2022) Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC Medical Research Methodology 22:1.
Crossref
Crossref
Malthe Faurschou Wandall-Holm, Mathias Due Buron, Tine Iskov Kopp, Karsten Thielen, Finn Sellebjerg & Melinda Magyari. (2022) Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 93:8, pages 858-864.
Crossref
Crossref
Sajjad Ghane Ezabadi, Mohammad Ali Sahraian, Hossein Maroufi, Mohammad Amin Shahrbaf & Sharareh Eskandarieh. (2022) Global assessment of characteristics of multiple sclerosis registries; A systematic review. Multiple Sclerosis and Related Disorders 63, pages 103928.
Crossref
Crossref
Asta Theodorsdottir, Birgit Debrabant, Melinda Magyari, Matthias Kant, Peter V Rasmussen, Carl-Fredrik Malmberg, Iver A Norberg, Victoria Hansen, Danny Bech, Mathias F Schmidt, Karen Schreiber, Jette L Frederiksen, Finn Sellebjerg & Zsolt Illes. (2021) Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. Multiple Sclerosis Journal 27:14, pages 2254-2266.
Crossref
Crossref
Pietro Iaffaldano, Giuseppe Lucisano, Helmut Butzkueven, Jan Hillert, Robert Hyde, Nils Koch-Henriksen, Melinda Magyari, Fabio Pellegrini, Tim Spelman, Per Soelberg Sørensen, Sandra Vukusic & Maria Trojano. (2021) Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Multiple Sclerosis Journal 27:10, pages 1543-1555.
Crossref
Crossref
Johanna Balslev Andersen, Tine Iskov Kopp, Finn Sellebjerg & Melinda Magyari. (2021) Pregnancy-Related and Perinatal Outcomes in Women With Multiple Sclerosis. Neurology: Clinical Practice 11:4, pages 280-290.
Crossref
Crossref
Nils Koch-Henriksen, Per Soelberg Sørensen & Melinda Magyari. (2021) Relapses add to permanent disability in relapsing multiple sclerosis patients. Multiple Sclerosis and Related Disorders 53, pages 103029.
Crossref
Crossref
Viktoria Papp, Mathias Due Buron, Volkert Siersma, Peter Vestergaard Rasmussen, Zsolt Illes, Matthias Kant, Claudia Hilt, Zsolt Mezei, Homayoun Roshanisefat, Tobias Sejbæk, Arkadiusz Weglewski, Janneke van Wingerden, Svend Sparre Geertsen, Stephan Bramow, Finn Sellebjerg & Melinda Magyari. (2021) Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry. PLOS ONE 16:5, pages e0250820.
Crossref
Crossref
Mathias Due Buron, Tomas Kalincik, Finn Sellebjerg, Per Soelberg Sørensen & Melinda Magyari. (2021) Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. Journal of Neurology, Neurosurgery & Psychiatry 92:5, pages 556-562.
Crossref
Crossref
Per Soelberg Sorensen, Tine Iskov Kopp, Hanna Joensen, Anna Olsson, Finn Sellebjerg & Melinda Magyari. (2021) Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS. Multiple Sclerosis and Related Disorders 50, pages 102813.
Crossref
Crossref
Holly C. Elser, Nils Koch-Henriksen & Melinda Magyari. (2021) Seasonal patterns of relapse and disability in Danish MS patients: A population-based cohort study. Multiple Sclerosis and Related Disorders 49, pages 102739.
Crossref
Crossref
Ditte Bang Oturai, Helle Bach Søndergaard, Nils Koch-Henriksen, Christina Andersen, Julie Hejgaard Laursen, Stefan Gustavsen, Joachim Tilsted Kristensen, Melinda Magyari, Per Soelberg Sørensen, Finn Sellebjerg, Lise Wegner Thørner, Henrik Ullum & Annette Bang Oturai. (2020) Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis. Multiple Sclerosis Journal 27:2, pages 188-197.
Crossref
Crossref
Melinda Magyari, Hanna Joensen, Bjarne Laursen & Nils Koch‐Henriksen. (2020) The Danish Multiple Sclerosis Registry. Brain and Behavior 11:1.
Crossref
Crossref
Janni Lisander Larsen, Jakob Schäfer, Helle Hvilsted Nielsen & Peter Vestergaard Rasmussen. (2020) Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis. BMJ Open 10:8, pages e037701.
Crossref
Crossref
Tine Iskov Kopp, Morten Blinkenberg, Thor Ameri Chalmer, Thor Petersen, Mads Henrik Ravnborg, Per Soelberg Sørensen & Melinda Magyari. (2019) Predictors of treatment outcome in patients with paediatric onset multiple sclerosis. Multiple Sclerosis Journal 26:8, pages 964-975.
Crossref
Crossref
Tine Iskov Kopp, Morten Blinkenberg, Thor Petersen, Per Soelberg Sorensen & Melinda Magyari. (2020) Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. Multiple Sclerosis and Related Disorders 40, pages 101956.
Crossref
Crossref
Mathias Due Buron, Melinda Magyari, Thor Ameri Chalmer, Per Soelberg Sørensen & Finn Sellebjerg. (2020) Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β. Multiple Sclerosis and Related Disorders 39, pages 101894.
Crossref
Crossref
Julie Laub Erdal, Tine Iskov Kopp, Morten Blinkenberg, Thor Petersen, Per Soelberg Sørensen & Melinda Magyari. (2020) Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis. Multiple Sclerosis and Related Disorders 37, pages 101431.
Crossref
Crossref
Peter Joseph Jongen. (2019) Observational designs in clinical multiple sclerosis research: Particulars, practices and potentialities. Multiple Sclerosis and Related Disorders 35, pages 142-149.
Crossref
Crossref
Magnus S. Boesen, Poul E.H. Jensen, Alfred P. Born, Melinda Magyari, Anna C. Nilsson, Christina Hoei-Hansen, Morten Blinkenberg & Finn Sellebjerg. (2019) Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008‒2018: A nationwide, population-based cohort study. Multiple Sclerosis and Related Disorders 33, pages 162-167.
Crossref
Crossref
Nils Koch-Henriksen, Lau Caspar Thygesen, Per Soelberg Sørensen & Melinda Magyari. (2019) Worsening of disability caused by relapses in multiple sclerosis: A different approach. Multiple Sclerosis and Related Disorders 32, pages 1-8.
Crossref
Crossref
Mathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, Jette Frederiksen, Monika Katarzyna Góra, Zsolt Illes, Matthias Kant, Zsolt Mezei, Thor Petersen, Peter Vestergaard Rasmussen, Homayoun Roshanisefat, Houry Hassanpour-Kalam-Roudy, Tobias Sejbæk, Anna Tsakiri, Arkadiusz Weglewski, Per Soelberg Sorensen & Melinda Magyari. (2019) Comparative effectiveness of teriflunomide and dimethyl fumarate. Neurology 92:16, pages e1811-e1820.
Crossref
Crossref
M. Nørgaard, K. Veres, E.M. Didden, D. Wormser & M. Magyari. (2019) Multiple sclerosis and cancer incidence: A Danish nationwide cohort study. Multiple Sclerosis and Related Disorders 28, pages 81-85.
Crossref
Crossref
Johanna Balslev Andersen, Julie Yoon Moberg, Tim Spelman & Melinda Magyari. (2018) Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study. Frontiers in Immunology 9.
Crossref
Crossref
IC Hasselbalch, HB Søndergaard, N Koch-Henriksen, A Olsson, H Ullum, F Sellebjerg & AB Oturai. (2018) The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:4, pages 205521731881318.
Crossref
Crossref
T. A. Chalmer, L. M. Baggesen, M. Nørgaard, N. Koch‐Henriksen, M. Magyari & P. S. Sorensen. (2018) Early versus later treatment start in multiple sclerosis: a register‐based cohort study. European Journal of Neurology 25:10, pages 1262.
Crossref
Crossref
S. G. Berntsson, A. Kristoffersson, I. Boström, A. Feresiadou, J. Burman & A. M. Landtblom. (2018) Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?. Acta Neurologica Scandinavica 138:4, pages 327-331.
Crossref
Crossref
Eva R. Petersen, Annette B. Oturai, Nils Koch-Henriksen, Melinda Magyari, Per S. Sørensen, Finn Sellebjerg & Helle B. Søndergaard. (2018) Smoking affects the interferon beta treatment response in multiple sclerosis. Neurology 90:7, pages e593-e600.
Crossref
Crossref